Last reviewed 2026-05-18 · How we verify

Feru-guard 100M

Glovia Co., Ltd. · Phase 2 active Small molecule Quality 35/100

Feru-guard 100M is a Nutritional supplement Small molecule drug developed by Glovia Co., Ltd.. It is currently in Phase 2 development.

Feru-guard 100M is believed to provide antioxidant and anti-inflammatory effects through ferulic acid and related compounds.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Feru-guard 100M
Sponsor	Glovia Co., Ltd.
Drug class	Nutritional supplement
Modality	Small molecule
Phase	Phase 2

Mechanism of action

The formulation contains ferulic acid, a phenolic compound found in plant cell walls, which may exert neuroprotective effects through antioxidant activity and reduction of oxidative stress. The exact molecular targets and mechanisms in clinical applications remain under investigation.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Feru-guard for Behavioral Symptoms in Dementia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Feru-guard 100M CI brief — competitive landscape report
Feru-guard 100M updates RSS · CI watch RSS
Glovia Co., Ltd. portfolio CI

Frequently asked questions about Feru-guard 100M

What is Feru-guard 100M?

Feru-guard 100M is a Nutritional supplement drug developed by Glovia Co., Ltd..

How does Feru-guard 100M work?

Feru-guard 100M is believed to provide antioxidant and anti-inflammatory effects through ferulic acid and related compounds.

Who makes Feru-guard 100M?

Feru-guard 100M is developed by Glovia Co., Ltd. (see full Glovia Co., Ltd. pipeline at /company/glovia-co-ltd).

What drug class is Feru-guard 100M in?

Feru-guard 100M belongs to the Nutritional supplement class. See all Nutritional supplement drugs at /class/nutritional-supplement.

What development phase is Feru-guard 100M in?

Feru-guard 100M is in Phase 2.

Drug class: All Nutritional supplement drugs
Manufacturer: Glovia Co., Ltd. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing